Gilead Sciences (NASDAQ:GILD) (NASDAQ: GILD) is a biopharmaceutical company headquartered in Foster City, California, specializing in the research, development and commercialization of innovative therapeutics. The company’s core business activities focus on antiviral treatments, with a robust portfolio addressing HIV, viral hepatitis B and C, and more recently COVID-19 through its investigational and approved therapies. Gilead’s leading antiviral products include Biktarvy and Truvada for HIV, Viread for hepatitis B, and Veklury (remdesivir), which received emergency use authorization for COVID-19 treatment.
Since its founding in 1987 by Dr. Michael L. Riordan, Gilead has expanded into oncology and cell therapy, notably advancing CAR-T treatments such as Yescarta for certain blood cancers. The company’s global operations span North America, Europe, Asia and Latin America, supported by research facilities and commercial offices in key markets. Gilead maintains strategic partnerships and licensing agreements to enhance access to its medicines, particularly in low- and middle-income countries.
Under the leadership of President and CEO Daniel O’Day, who joined the company in 2019, Gilead has intensified its focus on pipeline innovation, investing in next-generation antivirals, immuno-oncology and anti-fibrotic therapies. The company’s R&D efforts are centered around translational science and precision medicine, leveraging advanced platforms to identify new molecular targets and accelerate clinical development. Gilead’s commitment to patient access, scientific collaboration and regulatory excellence continues to drive its mission of delivering transformative therapies worldwide.
